Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasHodgkin LymphomaIndolent LymphomasDiseaseHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupICD10C81.-C82.-C82.7C82.9C83.1C83.3C84.4MeSHLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, T-Cell, PeripheralSequenceChemotherapyChemo-substanceCarboplatinCytarabineDexamethasoneGemcitabineRituximabChemo-substanceCarboplatinCytarabineDexamethasoneGemcitabineRituximabChemo-substanceCarboplatinCytarabineDexamethasoneGemcitabineRituximabChemo-substanceCarboplatinCytarabineDexamethasoneGemcitabineRituximabNo. Substances34 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneNo. Substances57Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationSecond lineseveral possibleTherapy phaseInductionTherapy intentioncurativeRisksAnemia Hb below 8g/dlCardiotoxicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityInfectionsNeuropathyNeurotoxicityNeutropeniaPainSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorGopal ATessoulin BDiseaseB-Non-Hodgkin-Lymphom/Hodgkin LymphomNon-Hodgkin-Lymphom / Hodgkin Lymphomrezidivierendes oder refraktäres Non-Hodgkin-Lymphom, ECOG 0-2OriginNantes Medical University, Nantes, FranceUniversity of Washington/Fred Hutchinson Cancer Research Center, Seattle, WAProtocols in Revision 3 protocols foundProtocols under revision.DHAC - Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, Non-Hodgkin Lymphoma / Hodgkin Lymphoma. (PID2346 V1.0)R-DHAC - Rituximab 375 / Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, B-Non-Hodgkin's Lymphoma/Hodgkin's Lymphoma (PID2345 V1.0)R-GDC - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Carboplatin 5, diffuse large B-non-Hodgkin Lymphoma (PID1681 V1.0)
